Platelets are pivotal in the pathogenesis of acute coronary syndrome and in the complications following the implantation of coronary stents. Dual antiplatelet therapy with aspirin and clopidogrel is essential to reduce the risk of recurrent ischaemic events. The combination should be taken for up to one year following acute coronary syndrome in patients at high risk of future events. Aspirin should be continued indefinitely. The duration of treatment with clopidogrel depends on the type of stent implanted. Patients with drug-eluting stents require combination therapy for at least one year. Premature withdrawal of antiplatelet therapy carries a risk of thrombosis in the stent. In patients with drug-eluting stents, thrombosis may occur as a late complication of stent implantation. Withdrawal of antiplatelet therapy should be done in consultation with the cardiologist who implanted the drug-eluting stent.
Introduction
The term 'acute coronary syndrome' encompasses the spectrum of unstable angina and myocardial infarction with or without elevation of the ST segment of the ECG. These conditions share a common aetiology, usually rupture of an atherosclerotic plaque, activation of the coagulation cascade with platelet thrombus formation and vessel occlusion possibly with distal embolisation.
Contemporary medical therapy in these patients includes combination antiplatelet therapy, beta blockers, angiotensin converting enzyme inhibitors and cholesterol lowering drugs.
Despite optimal medical therapy a significant proportion of patients develop recurrent angina and re-infarction. An 'invasive strategy' has therefore been adopted whereby early coronary angiography is undertaken and in those with suitable coronary anatomy (namely flow limiting coronary stenoses in important sized coronary vessels) coronary revascularisation is performed.
This may either be percutaneous coronary intervention (see box) or coronary artery bypass grafting surgery depending on the nature and extent of coronary disease. Such an approach reduces the rates of recurrent angina and myocardial infarction.
Both acute coronary syndrome and percutaneous intervention are associated with high levels of platelet activation. Effective antiplatelet therapy is therefore essential to reduce the risk of recurrent vascular events.
Antiplatelet drugs
Platelets are activated by a number of pathways. When there is marked platelet activation, combinations of antiplatelet drugs are required to inhibit platelet function (Fig. 1 ).
Aspirin
Aspirin acts by irreversibly inactivating platelet cyclo-oxygenase 
Clinical data
The Antithrombotic Trialists' Collaboration showed that in patients with acute coronary syndrome aspirin is associated with a relative reduction of recurrent vascular events by about 25%. In patients with unstable angina, without myocardial infarction, the benefit is even greater. 1 
Dose and duration

Clinical data
The combination of clopidogrel with aspirin is synergistic providing more complete platelet inhibition than with either drug alone. After nine months of treatment in patients with non ST elevation acute coronary syndrome, the combination of clopidogrel plus aspirin provided a 20% relative risk reduction in death, myocardial infarction or stroke compared to aspirin alone. 4 The combination was of benefit regardless of whether or not a stent was implanted. In patients with ST elevation myocardial infarction receiving thrombolytic therapy, the combination of clopidogrel and aspirin provided superior outcomes compared with aspirin alone. 5 The optimal duration of combination therapy in this setting is unknown.
Adverse effects
Clopidogrel can cause gastrointestinal symptoms and skin rash.
The combination of aspirin and clopidogrel is associated with a 1% absolute increase in major, non-life-threatening bleeding per year compared to aspirin alone.
Ticlopidine
This drug is now rarely used given its adverse effect profile of gastrointestinal upset, neutropenia (in 2.4% of cases) and rare cases of thrombotic thrombocytopenic purpura. It is an alternative in the rare situation of intolerance to clopidogrel.
Haematological monitoring should be undertaken every two weeks during the first four months of therapy to watch for neutropenia.
Glycoprotein IIb/IIIa receptor antagonists
The glycoprotein IIb/IIIa receptor located on the platelet surface 
Other antiplatelet drugs
Dipyridamole and sulfinpyrazone confer no additional benefit in acute coronary syndrome and are not recommended.
Antiplatelet therapy following acute coronary syndrome (without coronary stent implantation)
In patients with non ST elevation acute coronary syndrome, 12 months of clopidogrel is recommended. In patients with ST elevation myocardial infarction who are not undergoing coronary stenting the optimal duration is unclear.
Antiplatelet therapy after coronary stenting
Coronary stent implantation is associated with two potentially adverse sequelae. The first is stent thrombosis. Coronary stents are inherently thrombogenic and dual antiplatelet therapy is essential to reduce the risk of thrombosis in the stent. This risk is greatest early after implantation when platelet activity is maximal and diminishes once endothelialisation of the stent occurs. The second adverse consequence of stent implantation is restenosis. Restenosis is defined as gradual renarrowing within the stent secondary to neointimal proliferation and usually occurring within 2-8 months of stent implantation.
It has been dramatically reduced with the introduction of drug-eluting stents. These stents elute antiproliferative drugs such as sirolimus and paclitaxel which suppress the growth of neointimal tissue ( Table 1) . As a consequence adequate endothelialisation may be delayed thus the duration of dual antiplatelet therapy needs to be longer than with bare metal stents.
The usual antiplatelet regimen consists of aspirin (at least 75 mg/day) indefinitely and clopidogrel (75 mg/day). If stent implantation was for non ST elevation acute coronary syndrome then combination therapy is beneficial for at least one year. 4 If implantation was elective the duration of clopidogrel therapy depends on the stent type.
Non-drug-eluting stents
Bare metal stents require a shorter duration of combination therapy than drug-eluting stents. Initial data suggested that clopidogrel be prescribed in conjunction with aspirin for a minimum duration of one month. However, data from the Table 1 Available drug-eluting stents
Stent name Antiproliferative drug
Cypher sirolimus
Taxus paclitaxel Endeavor zotarolimus
Xience V everolimus CREDO study show a small but definite benefit from one year of dual antiplatelet therapy following elective bare metal stent implantation. 6 One year of therapy may therefore be considered in patients with more extensive vascular disease.
Drug-eluting stents
A longer duration of combination antiplatelet therapy is required because the drug in the stent delays endothelialisation. Initial data from trials suggested clopidogrel be continued for a minimum of 3-6 months following implantation of a stent.
However, data are emerging that drug-eluting stents are associated with a slightly increased risk of late stent thrombosis
(1 in 500 patient-years increased risk). 7 Incomplete or delayed stent endothelialisation due to drug inhibition of neointimal growth is at least partly responsible for this phenomenon.
Late stent thrombosis is serious and usually presents as 
Recommendations
All patients should take low-dose aspirin indefinitely if possible.
The duration of clopidogrel depends on the clinical situation.
One approach to therapy with clopidogrel is: 
Antiplatelet therapy and non-cardiac surgery after coronary stenting
Patients taking antiplatelet drugs may need surgery.
Unfortunately, some patients may be routinely instructed to stop 'blood thinners' prior to surgery without proper assessment of the risk involved in terms of stent thrombosis (and therefore myocardial infarction or death). If clopidogrel must be stopped before major surgery, consider continuing to give aspirin throughout the operation and restarting clopidogrel as soon as possible.
Recommendations
Important questions to ask when a patient who has a stent needs surgery:
n Is the procedure necessary?
n Can the procedure be performed if dual antiplatelet therapy is continued?
n Can the procedure be performed on aspirin monotherapy?
n Can the procedure be delayed to minimise the risk of stent thrombosis?
In the patient who has a bare metal stent implanted, there is an appreciable risk of stent thrombosis if antiplatelet therapy is ceased before six weeks (incidence 3%). Antiplatelet therapy should therefore not be ceased for minor bleeding and elective procedures should be deferred for at least six weeks.
In the patient with a drug-eluting stent, given the concerns regarding late stent thrombosis, we recommend that elective surgery should be delayed for 12 months if possible. As One year after stopping alendronate the symptoms recurred.
A repeat CT scan showed extension of the necrosis without bone reformation. The involved implant and soft tissue were curetted under general anaesthesia. The wound healed slowly (see Fig. 1 ).
Comment
In this case alendronate was commenced before bisphosphonate-associated osteonecrosis of the jaw had been described. 1 Osteonecrosis associated with a previously stable implant was one of the first such presentations in Australia.
Bisphosphonate-associated osteonecrosis of the jaws is now defined as an area of exposed bone in the jaws which persists for more than eight weeks. Other conditions, including osteoradionecrosis and the presence of tumour, need to be excluded. The first described cases were in older, medically compromised patients treated with intravenous infusions
